[1] Phillips EJ, Sukasem C, Whirl-Carrillo M,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine:2017 Update[J]. Clin Pharm Thera, 2018,103:574-581.
[2] Meng LY, Wang CM, Jiang ZH,et al. HLA-B*1502 gene analysis and drug risk assessment in 140 children with epilepsy[J].Herald Med (医药导报),2018,37(11):1409-141.
[3] Sun D, Yu CH, Liu ZS,et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China[J]. J Huazhong Univ Sci Tech (Med Sci), 2014, 34(1):146-150.
[4] Guo H, Chen C, Deng TY,et al. Toxic epidermal necrolysis caused by oxacillin and analysis of negative cases of HLA-B* 1502[J].Herald Med (医药导报),2016,35(12):1317-1320.
[5] Tonekaboni SH, Jafari N, Mansouri M,et al. HLA-B*1502 in Iranian Children with Anticonvulsant Drugs-Induced Skin Reactions[J]. Iran J Child Neurol, 2017, 11(2):26-30.
[6] Song JS, Kang ES, Joo EY,et al. Absence of HLA-B*1502 and HLA-A*3101 alleles in 9 Korean patients with antiepileptic drug-induced skin rash:a preliminary study[J]. Ann Lab Med, 2014, 34(5):372-375.
[7] Amstutz U, Shear NH, Rieder MJ,et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions[J]. Epilepsia, 2014, 55(4):496-506.
[8] Dao RL, Su SC, Chung WH. Recent advances of pharmacogenomics in severe cutaneous adverse reactions:immune and nonimmune mechanisms[J]. Asia Pacific Allergy, 2015, 5(2):59-67.
[9] Sakurada K, Kozaru T, Yamada K,et al. Allergy to chlorpromazine and valproic acid following carbamazepine hypersensitivity in a patient with an HLA-B*4601 allele[J]. Neuropsychiatr Dis Treat, 2018, 14:1139-1142.